Side-by-side · Research reference
ChonlutenvsFOXO4-DRI
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-MechanisticHUMAN-REVIEWED8/38 cited
BAnimal-StrongHUMAN-REVIEWED12/45 cited
Chonluten
Khavinson Bioregulator · Bronchial Mucosa
Oral · Sublingual · Per Protocol
FOXO4-DRI
Senolytic Peptide · D-Retro-Inverso
SQ · Animal models only
01Mechanism of Action
Parameter
Chonluten
FOXO4-DRI
Primary target
Bronchial epithelial cells and respiratory mucosa tissue complexes
FOXO4-p53 protein complex in senescent cellsBourgeois 2025Tripathi 2021
Pathway
Bioregulatory peptide interaction → modulation of proliferative and inflammatory pathways in monocyte/macrophage populationsAvolio 2022
FOXO4-DRI binds disordered p53 transactivation domain → displaces FOXO4 → nuclear p53 exclusion → p53-mediated apoptosis in senescent cells
Downstream effect
Regulation of proliferative activity and inflammatory mediator production in respiratory-associated immune cellsAvolio 2022
Selective apoptosis of senescent cells; clearance restores tissue homeostasisTripathi 2021Alameen 2026
Feedback intact?
—
—
Origin
Khavinson bioregulator peptide complex derived from bronchial mucosa tissue extract methodology
D-retro-inverso modification — inverted amino acid sequence, D-amino acids for protease resistance
Antibody development
—
—
02Dosage Protocols
Parameter
Chonluten
FOXO4-DRI
Typical protocol dose
10–20 mg / day
Russian bioregulator tradition dosing; not standardized in Western literature.
—
Frequency
Once or twice daily
—
Route
Oral (capsule) or sublingual
Sublingual claimed for enhanced bioavailability; not validated.
SQ (animal)
No human route established.
Evidence basis
In vitro mechanistic
Animal / mechanistic
Duration
10–30 days per cycle
Traditional Khavinson protocol; cyclic administration common.
Weeks to months (animal studies)
Senescent cell clearance observed within weeks.
Clinical validation
None (PubMed indexed)
—
Animal dose (mouse)
—
5 mg/kg
SQ injection, aged mouse model (testosterone restoration).
Frequency (animal)
—
Variable — single or intermittent dosing
Protocol-dependent; no standardised regimen.
Human equivalent (theoretical)
—
~0.4 mg/kg (28 mg / 70 kg adult)
Extrapolated using allometric scaling; no clinical validation.
Clinical status
—
No human trials completed
04Side Effects & Safety
Parameter
Chonluten
FOXO4-DRI
Documented adverse events
No published safety data in PubMed-indexed literature
—
Theoretical risks
Peptide hypersensitivity, GI intolerance (uncharacterized)
—
Drug interactions
Unknown — no pharmacokinetic studies available
—
Pregnancy / lactation
No data — avoid
—
Pulmonary hypertension risk
—
Senescent cell elimination promoted PH development/progression in rodent modelsBorn 2023
Context-dependent toxicity
—
Beneficial effects may be tissue/context-specific; elimination not universally protectiveBorn 2023
Off-target apoptosis
—
Theoretical risk of non-senescent cell apoptosis (selectivity not absolute)
Immune perturbation
—
Senescent cells contribute to immune surveillance; clearance effects unknown
Human safety unknown
—
No clinical trials — toxicity profile in humans not established
Absolute Contraindications
Chonluten
- ·Known hypersensitivity to peptide components
FOXO4-DRI
- ·Pulmonary hypertension or vascular disease (preclinical evidence of harm)Born 2023
- ·Pregnancy / lactation (no safety data)
Relative Contraindications
Chonluten
- ·Pregnancy and lactation (insufficient data)
- ·Active malignancy (theoretical bioregulator concern)
FOXO4-DRI
- ·Active malignancy (senescence as tumour suppressor mechanism)
- ·Wound healing / tissue repair (senescent cells involved in fibrosis resolution)
05Administration Protocol
Parameter
Chonluten
FOXO4-DRI
1. Preparation
Typically supplied as capsules or sublingual tablets. No reconstitution required. Store in cool, dry place away from light.
Subcutaneous injection used in rodent models. No human administration protocol exists.
2. Oral route
Swallow capsule with water, 20–30 minutes before meals or as directed. Traditional Khavinson protocol emphasizes empty stomach for absorption.
Typically reconstituted in sterile saline or PBS for animal experiments. Stability data limited.
3. Sublingual route
Place tablet under tongue, allow dissolution for 1–2 minutes. Avoid swallowing immediately. Claimed to bypass first-pass metabolism.
Variable — single bolus or intermittent dosing over weeks. No standardised human protocol.
4. Timing
Morning dose preferred; may split into twice-daily if higher dose used. Consistency emphasized in bioregulator protocols.
No registered human trials. Commercialisation by Cleara Biotech (Netherlands) in development phase.
5. Cycle protocol
10–30 day cycles common in Russian tradition. Rest period of 1–3 months between cycles often recommended, though no published evidence for this approach.
Would require cardiovascular assessment, pulmonary function, immune panel, tumour surveillance if human trials proceed.